Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.99 EPS (ttm)2.81 Insider Own9.30% Shs Outstand2.58B Perf Week0.55%
Market Cap225.41B Forward P/E16.47 EPS next Y5.30 Insider Trans0.00% Shs Float2.56B Perf Month5.01%
Income6.68B PEG4.88 EPS next Q1.19 Inst Own11.20% Short Float0.09% Perf Quarter1.71%
Sales49.53B P/S4.55 EPS this Y-2.80% Inst Trans0.10% Short Ratio1.47 Perf Half Y3.46%
Book/sh30.97 P/B2.82 EPS next Y9.78% ROA5.00% Target Price93.00 Perf Year24.34%
Cash/sh- P/C- EPS next 5Y6.36% ROE9.40% 52W Range69.53 - 87.29 Perf YTD3.87%
Dividend2.72 P/FCF39.82 EPS past 5Y-5.80% ROI7.30% 52W High-0.09% Beta0.71
Dividend %3.12% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.70% 52W Low25.43% ATR0.77
Employees121000 Current Ratio1.10 Sales Q/Q2.80% Oper. Margin16.20% RSI (14)64.57 Volatility0.86% 0.75%
OptionableYes Debt/Eq0.42 EPS Q/Q9.20% Profit Margin13.50% Rel Volume1.63 Prev Close87.00
ShortableYes LT Debt/Eq0.32 EarningsJan 24 BMO Payout95.80% Avg Volume1.50M Price87.21
Recom2.50 SMA202.12% SMA503.11% SMA2005.19% Volume2,446,553 Change0.24%
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-23-18 05:10PM  Key Updates on Novartiss Kymriah Market Realist
04:37PM  Novartis Announces Positive Results on Migraine Candidate Zacks
03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
10:32AM  Novartis on the Street: Analyst Ratings and Recommendations Market Realist
09:48AM  Celgene, Novartis Both Report Billion Dollar Buyouts Market Exclusive
09:38AM  The Top 5 Johnson & Johnson Shareholders (JNJ) Investopedia
09:05AM  Why Celgene's Acquisition Of Juno Matters For Biotech And Investors Forbes
09:03AM  Reading the Estimates for Novartiss Alcon in 4Q17 Market Realist
07:34AM  Whats Expected of Novartiss Sandoz Segment in 4Q17? Market Realist
03:06AM  Teva Pharmaceutical Industries Ltd -- Moody's: European generic drug market growth to continue into 2020 on patent expiries, rising usage Moody's
Jan-22-18 11:30AM  Behind Novartiss 4Q17 Estimates: Innovative Medicines Market Realist
10:32AM  Analyst Ratings and Recommendations for Johnson & Johnson Market Realist
10:12AM  What's in the Cards for Novartis (NVS) This Earnings Season? Zacks
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
08:25AM  Inside Novartiss 4Q17 Earnings: Analyst Estimates Market Realist
07:34AM  Johnson & Johnson Is Trading at an All-Time HighWhats Next? Market Realist
07:07AM  These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition Motley Fool
01:02AM  Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period GlobeNewswire
Jan-19-18 10:23AM  Cancer Space Update: Label Expansions, Data Readouts in Focus Zacks
07:33AM  How Is Bristol-Myers Squibbs Sprycel Positioned for 2018? Market Realist
07:30AM  Amgens Aimovig is Expected to Witness Steady Growth in 2018 Market Realist
07:00AM  Blog Exposure - FDA Granted Priority Review to Novartis Kymriah(TM) for Adults with relapsed/refractory B-cell lymphoma ACCESSWIRE
05:55AM  Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion Zacks
Jan-18-18 05:30PM  Merck & Co.s Business Segments and Performance in 3Q17 Market Realist
01:55PM  3 Biotech Stocks Start Healthy in 18: Will the Rally Last? InvestorPlace
11:30AM  Why Opdivo Could Continue to Be Growth Driver beyond 2018 Market Realist
10:30AM  A Look into Amgens Collaborations in 2H17 Market Realist
10:00AM  Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018 Market Realist
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
08:29AM  How Opdivo Is Positioned at the Beginning of 2018 Market Realist
08:15AM  Heres Whats Moving Novartis And Aeterna Zentaris Right Now Market Exclusive
07:56AM  Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA Zacks
07:00AM  Biocon Inks Deal With Novartis After U.S. Nod for Biologic Drug Bloomberg
Jan-17-18 12:53PM  Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense Investor's Business Daily
09:01AM  Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients Market Realist
07:31AM  Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline Market Realist
07:30AM  Teva Pharmaceutical: Still Focused on New Product Launches Market Realist
02:15AM  Novartis's Kymriah wins speedy reviews in U.S., Europe Reuters
Jan-16-18 09:00AM  How Teva Pharmaceutical Plans to Improve Financial Profile Market Realist
08:35AM  Novartis (NVS) Announces Acceptance of Humira BLA by the FDA Zacks
Jan-12-18 10:08PM  Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride Motley Fool
11:20AM  The Key Challenges Teva Pharmaceutical Is Facing Market Realist
09:01AM  What Analysts Recommend for Roche in January 2018 Market Realist
07:32AM  Zelboraf Could Boost Roches Sales Growth in 2018 Market Realist
Jan-11-18 10:32AM  Approval of Alecensa in Europe Could Boost Roches Revenue Growth Market Realist
Jan-10-18 01:37PM  Perjeta Could Significantly Boost Roches Revenue Growth in 2018 Market Realist
12:35PM  Novartis becomes latest big-name collaborator for Chapel Hill company American City Business Journals
09:36AM  Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar Zacks
09:05AM  Ignyta and Its Key Risks in 2018 Market Realist
09:00AM  Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology Market Realist
07:37AM  Inside Ignytas Financial Performance Market Realist
Jan-09-18 03:45PM  Ignytas Drug Pipeline Market Realist
02:15PM  A Close Look at Ignytas Licensing Agreement Market Realist
02:10PM  AbbVie Expects Peak Sales of $7 Billion for Imbruvica Market Realist
01:25PM  Assessing Incytes 3Q17 Product Portfolio Market Realist
12:41PM  Analyst Recommendations for Ignyta and Its Peers in January 2018 Market Realist
11:55AM  How Was Incytes Revenue Stream in 3Q17? Market Realist
11:09AM  5 Companies Hit 52-Week Highs GuruFocus.com
10:32AM  Why AbbVie Is Focused on Expanding Risankizumabs Label for Multiple Immunology Indications Market Realist
10:31AM  Valeant on the Street: Analyst Recommendations in December 2017 Market Realist
Jan-08-18 07:33AM  How Did Novo Nordisks NovoMix and Human Insulin Perform in 2017? Market Realist
Jan-05-18 02:16PM  Why Momenta Pharmaceuticals Rallied 15.6% Today Motley Fool
09:48AM  Cancer Space Update: New Regulatory Status for 3 Major Drugs Zacks
Jan-04-18 04:35PM  How Is Novo Nordisks New Generation Insulin Segment Positioned after 3Q17? Market Realist
12:19PM  Why Juno Therapeutics Stock Cooled Off in December Motley Fool
10:55AM  Enough With the Excuses! Tesla Needs a New Magic Trick InvestorPlace
08:00AM  Novartis Gets Second Breakthrough Designation for Kisqali Zacks
Jan-03-18 06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
Dec-30-17 07:00AM  3 Biggest Breakthroughs in Cancer Treatment in 2017 Motley Fool
12:01AM  [$$] Glaxo: Expect a Speedy Recovery Barrons.com
Dec-29-17 08:17AM  Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis Zacks
Dec-28-17 01:45PM  Why Proctor & Gamble Co Stock Offers Long-Term Value for Investors InvestorPlace
02:13AM  Swiss stocks - Factors to watch on Dec 28 Reuters
01:49AM  BRIEF-China Pioneer Pharma Enters Agreement For Sale Of Ophthalmic Pharmaceutical Products Reuters
Dec-27-17 11:18PM  BRIEF-Luye Pharma Group Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch Reuters
08:30AM  Gadfly's 2017 Toast to the Departed Bloomberg
Dec-22-17 04:19PM  Allergan says court affirms patent loss to Sandoz on eye drug Reuters
03:09PM  Allergan says court affirms patent loss to Sandoz on eye drug Reuters
08:28AM  Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder Zacks
Dec-21-17 08:31PM  California court exposes drug makers to additional liability Associated Press
06:42PM  California court says Novartis can be sued over generic drug injuries Reuters
10:00AM  5 Milestones Of 2017 In The War On Cancer Forbes
Dec-20-17 08:33AM  3 Top Generic Drug Stocks to Consider Buying Now Motley Fool
Dec-19-17 08:01AM  3 Questions Keeping Juno Therapeutics' Investors Up at Night Motley Fool
Dec-18-17 05:52PM  Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31 Zacks
08:55AM  Ultragenyx sells rare drug voucher for $130 mln to Novartis MarketWatch
Dec-15-17 04:28PM  CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More Zacks
02:05PM  Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations Zacks
01:56PM  ETFs with exposure to Novartis AG : December 15, 2017 Capital Cube
01:20PM  Beware: Price Wars For Big Pharma, Biotech Companies On Horizon Investor's Business Daily
Dec-13-17 12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
09:43AM  Novartis generics arm says may sell or end some products Reuters
Dec-12-17 05:39PM  Novartis Announces Positive Data on Sickle Cell Disease Drug Zacks
07:14AM  ASH 2017: CAR-T Wallops Blood Cancer Motley Fool
Dec-11-17 05:59PM  Novartis Reports Updated Results from Kymriah's JULIET Study Zacks
02:24PM  What's Causing Juno Therapeutics Shares to Tumble 11.9% Today Motley Fool
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
11:03AM  Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study PR Newswire
10:09AM  Gilead Sciences: Better Data, Better Stock? Barrons.com
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerJul 05Buy15.00266,6674,000,0052,544,182Jul 05 06:05 PM
Novartis Bioventures Ltd10% OwnerJun 19Sale22.023,22070,8992,251,457Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale21.2453,2001,130,2072,254,677Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale22.0070015,4002,307,877Jun 12 04:12 PM
Novartis Bioventures Ltd10% OwnerJun 07Sale22.114,840106,9992,308,577Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 06Sale22.987,274167,1612,313,417Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale23.114,780110,4882,320,691Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale23.4714,867348,9492,325,471Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 01Sale23.8910,722256,1762,340,338Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 31Sale23.9435,539850,8962,351,060Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 26Sale25.145,300133,2672,386,599May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 25Sale25.00531,3252,391,899May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 24Sale25.0117,451436,3642,391,952May 25 04:57 PM
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerMar 01Sale20.917,778162,6582,461,037May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 28Sale20.867,847163,6702,468,815May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 27Sale20.9657,8441,212,3062,476,662May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 24Sale20.935,398113,0002,534,506May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 23Sale21.044,999105,1602,539,904May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 22Sale21.8674916,3702,544,903May 02 05:22 PM